Sahajanand Medical Technologies Limited’s IPO listed at Rs 371.15 on the exchange, reaches a high of Rs 409.95

Mumbai - October 23, 2026: Shares of Surat-based Sahajanand Medical Technologies Limited, the Company has built a strong clinical foundation for its flagship products – Supraflex Cruz, Hydra, Sironity Drug-coated PTCA Balloon, Pipit and Cocoon, supported by 75 clinical studies (comprising 66 completed studies and 09 ongoing studies), as of June 30, 2026, across diverse geographies and patient populations was listed at Rs 368.05 on the BSE with a premium of 7% to the IPO price.

The scrip reached a high of Rs 409.95 on the NSE, and Rs 409.95 on the BSE.

The scrip closed at Rs 377.65 on the NSE and Rs 375 on BSE.

As per NSE, the total quantity traded stood at 13.02 lakh shares, on BSE the total Quantity stood at 174 lakh shares. Total Turnover (BSE+NSE) on Day 1 stood at Rs 709.55 crore.

The Market Capitalisation of the Company at today’s closing price stood at Rs 3,844.28 crore as per BSE and Rs. 3,838.69 crore as per NSE.

The issue received bids of 13,84,72,771 equity shares against the offered 97,50,482 equity shares, according to data available on the stock exchanges.

Qualified Institutional Buyers (QIB) and Retail Portion were subscribed 34.70 times and 3.03 times, respectively. Non-Institutional Investors (NII) portion was subscribed 14.64 times whereas the employee reserved portion subscribed 0.37 times.

About the Company

The Company was formed as a partnership firm in 1999, and thereafter incorporated as a joint stock company in 2001. The Company is a Class III and Class C/D medical devices company with a portfolio of technologically advanced medical devices across vascular and structural heart intervention. According to the report titled “Independent Market Research on Cardiovascular Devices Market” dated September 30, 2026, prepared and released by Frost & Sullivan (the “F&S Report”), the Company was the first in the world to receive a CE certification for a DES with a biodegradable polymer- based paclitaxel-eluting stent (Infinnium). Over the years, the Company has introduced several innovative products, driven by its focus on research and development and precision manufacturing capabilities enabling it to deliver quality products backed by clinical data, with a presence across 65 countries including India in the three months ended June 30, 2026 and 77 countries including India in Fiscal 2026.

It is a R&D-driven company engaged in the development of Class III and Class C/D medical devices, with an emphasis on vascular intervention (VI) and structural heart (SH). Its portfolio of VI products includes coronary intervention products such as coronary stents and coronary balloons, SH products include TAVI and occluders, and others including its own brand of renal stents, peripheral DCBs and other trading products.